Dual-payload ADCs are gaining traction, offering opportunities to overcome the tumour heterogeneity and resistance challenges faced by conventional ADCs.

Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), comparing cadonilimab plus chemot ...

Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology ...

The dual inhibition of PD-1 and VEGF pathways by ivonescimab aims to enhance immune response and limit tumor angiogenesis, ...

AUSTIN, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) -- via IBN - LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a biotech ...

A key number for Merck in the coming years is $70 billion. This is the mid-2030s revenue opportunity from potential new ...

Galderma (SIX: GALD) will present data on its innovative and industry-leading neuromodulator portfolio at the TOXINS 2026 International Conference in Madrid, Spain from January 14-17, 2026. The ...

In July 2025, a class 2 resubmission of tab-cel’s BLA was initiated by Atara Biotherapeutics, developer and sponsor of ...

Inhibrx Biosciences, Inc. stays a Strong Buy with Q2 2026 ozekibart BLA catalyst, 2026 PFS data, and Ewing sarcoma updates.

Breakthrough Therapy Designation granted for investigational therapy IPN60340 in combination with venetoclax and azacitidine in first line unfit acute myeloid leukemia PARIS, FRANCE, 13 JANUARY 2026 ...

What is different about their ovaries that allows them to continue ovulating for so long?” Could we harness those qualities to benefit human health? She had to find out. But obtaining samples of any ...

Immunotherapy is offering new hope for cancers that once had grim prognoses by harnessing the body's own immune system to ...